How should I order ferric sucrose (Ferrlecit) 125 mg intravenous infusion?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

How to Order Ferrlecit 125mg IV

Order Ferrlecit 125 mg (10 mL) diluted in 100 mL of 0.9% sodium chloride, administered as an intravenous infusion over 1 hour per dialysis session. 1

Ordering Specifications

Standard Adult Dosing

  • Dose: 125 mg elemental iron (10 mL of Ferrlecit)
  • Diluent: 100 mL of 0.9% sodium chloride (normal saline)
  • Infusion time: 1 hour
  • Frequency: Per dialysis session 1

Alternative Administration Method

If rapid administration is needed, Ferrlecit can be given undiluted as a slow IV injection at a rate of up to 12.5 mg/min (approximately 10 minutes for 125 mg dose) 1. However, the FDA label notes that individual doses exceeding 125 mg may be associated with higher incidence and/or severity of adverse events 1.

Critical Ordering Details

Do not mix Ferrlecit with other medications or add to parenteral nutrition solutions. Administer only in 0.9% saline 1.

Pre-Administration Requirements

Before ordering, ensure:

  • ☐ Confirm iron deficiency or iron deficiency anemia diagnosis
  • ☐ Review for previous drug allergies, including prior IV iron reactions
  • ☐ Check for severe asthma, eczema, or autoimmune conditions (increased hypersensitivity risk) 2
  • ☐ Ensure resuscitation equipment and emergency medications (epinephrine) are immediately available 2
  • ☐ Verify appropriate IV access with adequate cannula size (e.g., 20G) 2

Monitoring Requirements

  • Continuous observation for first 10-15 minutes of infusion 2
  • Monitor for hypersensitivity signs: pain at IV site, flushing, chest tightness, back pain, dyspnea, hypotension, urticaria 2
  • Reassess cannula site every 5-10 minutes during infusion 2

Important Safety Considerations

Dosing Caution

Research shows that doses of 250 mg or higher are associated with significantly increased adverse reactions (10-30% incidence) in a dose-dependent fashion 3. While some studies report safe administration of 250 mg doses over 1 hour 4, the FDA-approved dose remains 125 mg per session to minimize risk 1.

Contraindications

  • Iron overload (do not administer to patients with hemosiderosis) 1
  • Active or uncontrolled infection (generally avoided, though evidence suggests no clinically relevant infection risk increase in most populations) 2

Special Populations

  • Pediatric dosing: 0.12 mL/kg (1.5 mg/kg elemental iron) diluted in 25 mL 0.9% sodium chloride over 1 hour 1
  • Geriatric: Start at low end of dosing range due to decreased organ function 1
  • Benzyl alcohol content: Contains 9 mg/mL benzyl alcohol; use caution in neonates 1

Post-Infusion Care

  • Flush cannula with 10 mL normal saline before removal 2
  • Educate patient on delayed reactions (rash, dizziness, fever, joint pain) 2
  • Document dose, batch number, infusion time, and any adverse events 2

Laboratory Monitoring

Do not check iron parameters within 4 weeks of infusion as circulating iron interferes with assays 5. Evaluate CBC and iron parameters (ferritin, TSAT) at 4-8 weeks post-infusion 5. Hemoglobin should increase by 1-2 g/dL within 4-8 weeks of therapy 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.